Bleomycin clinical pharmacology by radioimmunoassay
- PMID: 6183016
- DOI: 10.1007/BF00296756
Bleomycin clinical pharmacology by radioimmunoassay
Abstract
Bleomycin pharmacokinetics were studied by radioimmunoassay in 11 patients who received 7-30 U intravenously (IV) and eight patients who received 4-30 U subcutaneously (SC). For patients who received IV bleomycin plasma disappearance was biphasic, with a mean initial half-life of 0.26 h and a terminal half-life of 2.3 h. Mean plasma drug clearance was 67.8 ml/min/m2 and the volume of distribution was 13.2 l/m2. Urinary excretion accounted for 63.9% of the drug in 24 h. After SC administration peak plasma levels occurred in 1.1 h, with a mean elimination half-life of 4.3 h. Mean plasma drug clearance was 60.5 ml/min/m2 and the volume of distribution was 19.2 l/m2. Bleomycin plasma clearance correlated well with serum creatinine (r2 = 0.72). Bleomycin has a rapid plasma elimination and urinary excretion. Bleomycin bioavailability after SC administration appears comparable to that seen after IV administration as determined by the areas under the plasma disappearance curves. Prolonged plasma levels are seen after SC injection, suggesting this route of administration can produce plasma concentrations comparable to those attained with continuous IV infusions.
Similar articles
-
Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay.Cancer. 1977 Dec;40(6):2772-8. doi: 10.1002/1097-0142(197712)40:6<2772::aid-cncr2820400603>3.0.co;2-1. Cancer. 1977. PMID: 73408
-
Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus.Cancer Treat Rep. 1977 Dec;61(9):1631-6. Cancer Treat Rep. 1977. PMID: 74282
-
Bleomycin disposition in children with cancer.Clin Pharmacol Ther. 1983 May;33(5):668-73. doi: 10.1038/clpt.1983.91. Clin Pharmacol Ther. 1983. PMID: 6188571
-
Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function.Cancer. 1977 Apr;39(4):1430-4. doi: 10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-v. Cancer. 1977. PMID: 66973
-
Subcutaneous infusion of bleomycin--a practical alternative to intravenous infusion.J Clin Oncol. 1987 Apr;5(4):648-50. doi: 10.1200/JCO.1987.5.4.648. J Clin Oncol. 1987. PMID: 2435856
Cited by
-
Phase I trial of tallysomycin S10b, a bleomycin analogue.Invest New Drugs. 1990 May;8(2):171-80. doi: 10.1007/BF00177253. Invest New Drugs. 1990. PMID: 1696567
-
Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P.J Immunol. 2007 Sep 15;179(6):4035-44. doi: 10.4049/jimmunol.179.6.4035. J Immunol. 2007. PMID: 17785842 Free PMC article.
-
Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.Clin Pharmacokinet. 1987 Oct;13(4):205-27. doi: 10.2165/00003088-198713040-00001. Clin Pharmacokinet. 1987. PMID: 3311530 Review.
-
Tumor size and effectiveness of electrochemotherapy.Radiol Oncol. 2013 Mar;47(1):32-41. doi: 10.2478/raon-2013-0002. Epub 2013 Feb 1. Radiol Oncol. 2013. PMID: 23450195 Free PMC article.
-
Management of cutaneous metastases using electrochemotherapy.Acta Oncol. 2011 Jun;50(5):621-9. doi: 10.3109/0284186X.2011.573626. Acta Oncol. 2011. PMID: 21574833 Free PMC article. Clinical Trial.